Torley Helen sold 10,711 shares of HALOZYME THERAPEUTICS, INC. at $101.09 for −$1.08M on Nov 12, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
PRESIDENT AND CEO
PRESIDENT AND CEO
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,082,807.12Shares × reported price
Shares traded
10,711Common Stock
Price per share
$101.09Reported price. Read footnotes for ranges.
% of reported position traded
1.36%This security and ownership context
Holdings after
777,069Direct
Trade date
Nov 12, 2026Sell
Filed
Nov 16, 2026, 8:33 PM ET5-day reporting delay
Accession
0001159036-26-000147Code S · Transaction 402327
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 787,780 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Option exercise20,000$18.41−$368,200Trade 402340
Nov 13, 2026Option exercise1,552$18.41−$28,572.32Trade 402341
Nov 13, 2026Option exercise18,448$16.65−$307,159.20Trade 402342
Nov 16, 2026Option exercise20,000$16.65−$333,000Trade 402343
Nov 12, 2026Option exercise20,000$18.41$368,200Trade 402326
Nov 13, 2026Option exercise1,552$18.41$28,572.32Trade 402329
Nov 13, 2026Option exercise18,448$16.65$307,159.20Trade 402330
Nov 16, 2026Option exercise20,000$16.65$333,000Trade 402333
Nov 12, 2026Sell9,289$101.49−$942,777.77Trade 402328
Nov 13, 2026Sell7,992$100.02−$799,351.85Trade 402331
Nov 13, 2026Sell12,008$100.61−$1,208,172.91Trade 402332
Nov 16, 2026Sell7,283$96.85−$705,343.98Trade 402334
Nov 16, 2026Sell4,802$97.96−$470,379.91Trade 402335
Nov 16, 2026Sell1,586$98.89−$156,841.13Trade 402336
Nov 16, 2026Sell4,897$100.10−$490,170.11Trade 402337
Nov 16, 2026Sell1,244$101.06−$125,717.40Trade 402338
Nov 16, 2026Sell188$101.72−$19,123.36Trade 402339
18 transaction rows in this filing. Joint filers share the same rows.

HALO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
HALO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +5.8%1w ago +19%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year terms expiring in February 2028 and February 2029. F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.340 to $101.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.340 to $101.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.337 to $100.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.360 to $101.066. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $96.440 to $97.420. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $97.490 to $98.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.520 to $99.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.703 to $100.650. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.710 to $101.643. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F11: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. F12: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 12, 2019.